TY - JOUR
T1 - ALDH2 as a potential stem cell-related biomarker in lung adenocarcinoma
T2 - Comprehensive multi-omics analysis
AU - Tran, Thi Oanh
AU - Vo, Thanh Hoa
AU - Lam, Luu Ho Thanh
AU - Le, Nguyen Quoc Khanh
N1 - Funding Information:
This work was supported by the National Science and Technology Council , Taiwan [grant numbers MOST110-2221-E-038-001-MY2 and MOST111-2628-E-038–002-MY3 ].
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/1
Y1 - 2023/1
N2 - Lung adenocarcinoma (LUAD) is the most prevalent lung cancer and one of the leading causes of death. Previous research found a link between LUAD and Aldehyde Dehydrogenase 2 (ALDH2), a member of aldehyde dehydrogenase gene (ALDH) superfamily. In this study, we identified additional useful prognostic markers for early LUAD identification and targeting LUAD therapy by analyzing the expression level, epigenetic mechanism, and signaling activities of ALDH2 in LUAD patients. The obtained results demonstrated that ALDH2 gene and protein expression significantly downregulated in LUAD patient samples. Furthermore, The American Joint Committee on Cancer (AJCC) reported that diminished ALDH2 expression was closely linked to worse overall survival (OS) in different stages of LUAD. Considerably, ALDH2 showed aberrant DNA methylation status in LUAD cancer. ALDH2 was found to be downregulated in the proteomic expression profile of several cell biology signaling pathways, particularly stem cell-related pathways. Finally, the relationship of ALDH2 activity with stem cell-related factors and immune system were reported. In conclusion, the downregulation of ALDH2, abnormal DNA methylation, and the consequent deficit of stemness signaling pathways are relevant prognostic and therapeutic markers in LUAD.
AB - Lung adenocarcinoma (LUAD) is the most prevalent lung cancer and one of the leading causes of death. Previous research found a link between LUAD and Aldehyde Dehydrogenase 2 (ALDH2), a member of aldehyde dehydrogenase gene (ALDH) superfamily. In this study, we identified additional useful prognostic markers for early LUAD identification and targeting LUAD therapy by analyzing the expression level, epigenetic mechanism, and signaling activities of ALDH2 in LUAD patients. The obtained results demonstrated that ALDH2 gene and protein expression significantly downregulated in LUAD patient samples. Furthermore, The American Joint Committee on Cancer (AJCC) reported that diminished ALDH2 expression was closely linked to worse overall survival (OS) in different stages of LUAD. Considerably, ALDH2 showed aberrant DNA methylation status in LUAD cancer. ALDH2 was found to be downregulated in the proteomic expression profile of several cell biology signaling pathways, particularly stem cell-related pathways. Finally, the relationship of ALDH2 activity with stem cell-related factors and immune system were reported. In conclusion, the downregulation of ALDH2, abnormal DNA methylation, and the consequent deficit of stemness signaling pathways are relevant prognostic and therapeutic markers in LUAD.
KW - Aldehyde Dehydrogenase 2
KW - Cancer stem cells
KW - DNA methylation
KW - Gene expression
KW - Lung adenocarcinoma
KW - Protein expression
KW - Survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85149435633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149435633&partnerID=8YFLogxK
U2 - 10.1016/j.csbj.2023.02.045
DO - 10.1016/j.csbj.2023.02.045
M3 - Article
AN - SCOPUS:85149435633
VL - 21
SP - 1921
EP - 1929
JO - Computational and Structural Biotechnology Journal
JF - Computational and Structural Biotechnology Journal
ER -
